SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-24-000012
Filing Date
2024-01-25
Accepted
2024-01-25 07:03:19
Documents
14
Period of Report
2024-01-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20240119.htm   iXBRL 8-K 37969
2 EX-99.1 a20240125pressrelease-653u.htm EX-99.1 17590
6 image_0a.jpg GRAPHIC 18662
  Complete submission text file 0001725160-24-000012.txt   218109

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20240119.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20240119_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20240119_pre.xml EX-101.PRE 13048
8 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20240119_htm.xml XML 2821
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 24558556
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)